Abbott's freestyle® libre is first and only cgm system to gain expanded reimbursement in japan to include all people with diabetes who use insulin

First and only continuous glucose monitoring (cgm) system with expanded coverage in japan will enable more people with diabetes to manage their condition without routine fingersticks1 associated with traditional blood glucose monitoring without expanded coverage, cgm reimbursements are limited to segment of people with diabetes who require insulin multiple times a day abbott park, ill., march 24, 2022  /prnewswire/ -- abbott (nyse: abt) today announced that the japanese ministry of health, labour and welfare has approved the expansion of reimbursement coverage for its freestyle® libre system to include all people with diabetes who use insulin at least once a day.
ABT Ratings Summary
ABT Quant Ranking